Sangamo Therapeutics' (SGMO) Buy Rating Reaffirmed at HC Wainwright

Sangamo Therapeutics (NASDAQ:SGMO - Get Free Report)'s stock had its "buy" rating reissued by analysts at HC Wainwright in a report issued on Monday,Benzinga reports. They presently have a $10.00 price target on the biopharmaceutical company's stock. HC Wainwright also issued estimates for Sangamo Therapeutics' Q1 2025 earnings at ($0.04) EPS, Q2 2025 earnings at $0.03 EPS, Q3 2025 earnings at ($0.11) EPS, Q4 2025 earnings at $0.00 EPS, FY2025 earnings at ($0.12) EPS, FY2026 earnings at ($0.21) EPS, FY2027 earnings at ($0.05) EPS, FY2028 earnings at $0.15 EPS and FY2029 earnings at $0.38 EPS.

A number of other equities research analysts have also recently commented on SGMO. Royal Bank of Canada restated a "sector perform" rating and set a $2.00 target price on shares of Sangamo Therapeutics in a research report on Tuesday, March 18th. Jefferies Financial Group dropped their price objective on Sangamo Therapeutics from $7.00 to $3.00 and set a "buy" rating on the stock in a report on Tuesday, December 31st. StockNews.com downgraded Sangamo Therapeutics from a "buy" rating to a "hold" rating in a research note on Tuesday, December 24th. Wells Fargo & Company dropped their price target on shares of Sangamo Therapeutics from $3.00 to $2.00 and set an "equal weight" rating on the stock in a research note on Tuesday, December 31st. Finally, Truist Financial reduced their price objective on shares of Sangamo Therapeutics from $7.00 to $5.00 and set a "buy" rating for the company in a research report on Thursday, January 23rd. Three equities research analysts have rated the stock with a hold rating and four have issued a buy rating to the company. According to data from MarketBeat, the company has an average rating of "Moderate Buy" and an average target price of $5.17.

Sangamo Therapeutics Stock Down 0.2 %

Shares of SGMO traded down $0.00 during mid-day trading on Monday, reaching $0.72. The company had a trading volume of 6,361,606 shares, compared to its average volume of 8,365,791. The stock has a market capitalization of $161.45 million, a P/E ratio of -0.96 and a beta of 1.57. Sangamo Therapeutics has a 52-week low of $0.30 and a 52-week high of $3.18. The stock has a 50 day moving average of $0.92 and a two-hundred day moving average of $1.39.

Sangamo Therapeutics (NASDAQ:SGMO - Get Free Report) last issued its quarterly earnings data on Monday, March 17th. The biopharmaceutical company reported ($0.11) EPS for the quarter, missing analysts' consensus estimates of ($0.09) by ($0.02). Sangamo Therapeutics had a negative return on equity of 264.16% and a negative net margin of 257.87%. The firm had revenue of $7.55 million for the quarter, compared to analyst estimates of $11.70 million. On average, sell-side analysts expect that Sangamo Therapeutics will post -0.46 earnings per share for the current year.

Institutional Investors Weigh In On Sangamo Therapeutics

Several institutional investors and hedge funds have recently added to or reduced their stakes in the business. Point72 Asset Management L.P. acquired a new stake in shares of Sangamo Therapeutics in the fourth quarter valued at about $2,316,000. Schonfeld Strategic Advisors LLC acquired a new stake in Sangamo Therapeutics in the 4th quarter valued at about $1,744,000. Acuta Capital Partners LLC acquired a new stake in Sangamo Therapeutics in the 4th quarter valued at about $755,000. Two Sigma Advisers LP purchased a new position in Sangamo Therapeutics in the 4th quarter worth approximately $722,000. Finally, Two Sigma Investments LP boosted its holdings in shares of Sangamo Therapeutics by 222.1% during the 4th quarter. Two Sigma Investments LP now owns 1,012,640 shares of the biopharmaceutical company's stock worth $1,033,000 after purchasing an additional 698,296 shares during the last quarter. Institutional investors and hedge funds own 56.93% of the company's stock.

About Sangamo Therapeutics

Sangamo Therapeutics, Inc, a clinical-stage genomic medicine company, focuses on translating science into medicines that transform the lives of patients and families afflicted with serious diseases in the United States. The company's clinical-stage product candidates are ST-920, a gene therapy product candidate, which is in Phase 1/2 clinical study for the treatment of Fabry disease; TX200, a chimeric antigen receptor engineered regulatory T cell (CAR-Treg) therapy product candidate that is in Phase 1/2 clinical study for the prevention of immune-mediated rejection in HLA-A2 mismatched kidney transplantation; SB-525, a gene therapy product candidate, which is in Phase 3 clinical trial for the treatment of moderately severe to severe hemophilia A; BIVV003, a zinc finger nuclease gene-edited cell therapy product candidate that is in Phase 1/2 PRECIZN-1 clinical study for the treatment of sickle cell disease.